« Return to News | Miscellaneous

Type I Diabetes Drug See Positive Results in Phase II

Thursday, January 24, 2008 10:11 AM

Diamyd Medical (formerly issued positive long-term results from a phase IIb trial of Diamyd, GAD-65), recombinant glutamic acid decarboxylase (GAD) delivered with alum for injection, for the treatment of type I diabetes. This randomized study enrolled seventy pediatric and adolescent subjects in Sweden.

The subjects received two single injections of Diamyd or placebo. The primary endpoint for the trial was the preservation of beta cell function as measured by C-peptide.

Thirty months after the first injection, preservation of insulin was significantly higher in subjects receiving Diamyd, both in the fasting state and after meal stimulation, compared with placebo-treated subjects.

Diamyd also increased GAD antibody levels at fifteen and twenty one months post-injection. Based on the data, phase III trials are planned.

The GAD gene technology was originally developed by the University of California, Los Angeles (UCLA). In 1997, BioSyn was granted an exclusive worldwide license to UCLA's GAD technology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.